GlassScriptPhysician profile
Yiling P Liu
NPI 1477579241
$539.36
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $75.79 · 2021: $72.19 · 2022: $42.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.99 | 2019-2020 | |
| Abbvie INC. | $114.33 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $74.65 | 2019-2020 | |
| Lilly USA, LLC | $50.60 | 2019-2020 | |
| Pfizer INC. | $48.49 | 2019 | |
| Amgen INC. | $32.47 | 2019 | |
| Astellas Pharma US INC | $30.03 | 2019 | |
| Amarin Pharma, INC. | $25.74 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.41 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.93 | 2019 | |
| Novo Nordisk INC | $11.72 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yiling Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.